SIGLEC16

Across TCGA pan-cancer cohorts, SIGLEC16 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SIGLEC16 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SIGLEC16 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SIGLEC16 expression acts as an unfavorable survival marker.

LUAD and SKCM are the cancer types where SIGLEC16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.045	0.717	<.001	26	view →
SKCM	DFS	Median	All	0.279	0.626	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SIGLEC16–LUAD (DFS)

Open the LUAD breakdown →